natgillin/translations-raw huggingface dataset:
This leaflet was last revised in month/YYYY Other sources of information
Ova uputa je zadnji puta revidirana u {MM/GGGG} Drugi izvori informacija
This leaflet was last revised in Other source of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information
Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova je uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova je uputa zadnji put revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova je uputa zadnji puta revidirana Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova uputa je posljednji puta revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova uputa je zadnji put revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information
Ova uputa je zadnji put revidirana u: Drugi izvori informacija
This leaflet was last revised in Other sources of information
Uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in Other sources of information:
Ova uputa je zadnji puta revidirana u Drugi izvori informacija:
This leaflet was last revised in XX/XXX.
Ova uputa je zadnji puta revidirana u MM/GGGG.
This leaflet was last revised in xxx
Ova je uputa zadnji put revidirana u xxx
This leaflet was last revised in xxxxxx
Uputa je zadnji puta revidirana u xxxxxx
This leaflet was last revised in {08/2016} Other sources of information
Ova uputa je zadnji puta revidirana u {08/2016} Drugi izvori informacija
This leaflet was last revised in {12/2014}.
Ova uputa je odobrena u {12/2014}.
This leaflet was last revised in {date}
Ova uputa je zadnji puta revidirana u
This leaflet was last revised in {MM YYYY}.
Ova uputa je zadnji puta revidirana u{MM GGGG}.
This leaflet was last revised in {MM/2016}.
Ova je uputa je zadnji puta revidirana u {MM/2016.}.
This leaflet was last revised in {MM/YYYY}
Ova uputa je posljednji puta revidirana u {MM/GGGG}
This leaflet was last revised in {MM/YYYY}
Ova uputa je zadnji puta revidirana u {mjesec GGGG}
This leaflet was last revised in {mm/yyyy}
Ova uputa je zadnji puta revidirana u {MM/GGGG}.
This leaflet was last revised in {MM/YYYY}
Ova uputa je zadnji puta revidirana u {MM/GGG}
This leaflet was last revised in {MM/YYYY}
Ova uputa je zadnji puta revidirana u:
This leaflet was last revised in {MM/YYYY} Other sources of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in {MM/YYYY} Other sources of information
Uputa je zadnji puta revidirana u {MM/GGGG} Drugi izvori informacija
This leaflet was last revised in {MM/YYYY}.
Ova uputa je zadnji put revidirana u {MM/GGGG
This leaflet was last revised in {MM/YYYY}.
Ova uputa je zadnji put revidirana u {MM/GGGG}
This leaflet was last revised in {MM/YYYY}.
Ova uputa je zadnji puta odobrena u {MM/GGGG}.
This leaflet was last revised in {MM/YYYY}.
Ova uputa je zadnji puta revidirana {MM/GGGG}
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta od
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta re
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta revidirana u MM GGGG}.
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta revidirana u:{MM/GGGG}
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta revidiranau {MM/GGGG}
This leaflet was last revised in {MM/YYYY}.
Uputa je zadnji puta revidiranau{MM/GGGG}
This leaflet was last revised in {MM/YYYY}..
Ova uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last revised in {month XXXX}
Ova uputa je zadnji put revidirana u {mjesec GGGG}
This leaflet was last revised in {month YYYY} Other sources of information
Ova uputa je zadnji puta revidirana Drugi izvori informacija
This leaflet was last revised in {month YYYY} Other sources of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in {month YYYY} Other sources of information
Ova uputa je zadnji puta revidirana u {mjesec GGGG} Ostali izvori informacija
This leaflet was last revised in {month YYYY}.
Ova je uputa zadnji puta revidirana u {mjesec GGGG}.
This leaflet was last revised in {month YYYY}.
Ova uputa je zadnji put revidirana {mjesec GGGG}.
This leaflet was last revised in {month YYYY}.
Ova uputa je zadnji puta revidirana u {mjesec GGGG}
This leaflet was last revised in {month YYYY}.
Uputa je zadnji puta revidirana u {mjesec/GGGG}.
This leaflet was last revised in {month/YYYY} Other sources of information
Ova uputa je zadnji puta revidirana u {mjesec GGGG} Drugi izvori informacija
This leaflet was last revised in.
Ova je uputa zadnji puta revidirana u.
This leaflet was last revised in: .
Ova uputa je zadnji puta revidirana u
This leaflet was last revised in: <Month YYYY>
Uputa je zadnji puta revidirana u <mjesec/GGGG.>
This leaflet was last revised in: Other sources of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised in: Other sources of information
Ova uputa je zadnji puta revidirana u: Drugi izvori informacija
This leaflet was last revised in{ MM/YYYY}.
Ova uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last revised in{MM/YYYY} Other sources of information
Ova uputa je zadnji puta revidirana u {MM/GGGG} Drugi izvori informacija
This leaflet was last revised mm/yyyy.
Ova uputa je zadnji puta revidirana u mm/gggg.
This leaflet was last revised on Other sources of information
Uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was last revised on {MM/YYYY}
Ova uputa je zadnji puta revidirana u {MM/GGGG}
This leaflet was last revised Other sources of information
Ova uputa je zadnji puta revidirana Drugi izvori informacija
This leaflet was last revisedin Other sources of information
Ova je uputa zadnji put revidirana u Drugi izvori informacija
This leaflet was last revisedin Other sources of information
Ova uputa je zadnji puta revidirana u Drugi izvori informacija
This leaflet was lastrevised in
Ova uputa je zadnji puta revidirana u
This leafletwas last revised in {MM/YYYY}
Ova uputa je zadnji put revidirana u {MM/GGGG}
This led to a decrease in the effectiveness of the medicine.
To je dovelo do smanjenja djelotvornosti lijeka.
This lets the empty syringe move up until the whole needle is covered by the needle guard (Figure 7).
Tako će se prazna štrcaljka povlačiti prema gore sve dok cijela igla ne bude prekrivena štitnikom (Slika 7).
This lets the powder in the capsule be released when you breathe in.
To omogućuje da se tijekom udisanja oslobodi prašak iz kapsule.
This LH/CG transmembrane receptor is a member of the super-family of G protein- coupled receptors; specifically, it has a large extra-cellular domain.
Ovaj transmembranski receptor LH/CG je član nadređene obitelji receptora udruženih s G proteinom; specifična mu je značajka velika izvanstanična domena.
This limits nerve damage caused by MS.
To ograničava oštećenje živaca koje uzrokuje MS.
This local reaction could be a swelling, an oedema or a nodule and resolves spontaneously within from 3 to 4 weeks at the most.
Te lokalne reakcije mogu biti oticanje, edem ili kvržica,koje spontano nestaju za 3-4 tjedna.
This lower dose is recommended for patients who cannot tolerate the higher dose
Ova niža doza preporučuje se za bolesnike koji ne podnose višu dozu.
This lower dose is recommended for patients who cannot tolerate the higher dose.
Ova niža doza preporučuje se za bolesnike koji ne podnose višu dozu
This lowers the heart’s need for oxygen especially in the situations when an angina attack is more likely to happen.
Time se smanjuje potreba srca za kisikom, osobito u situacijama kada postoji veća vjerojatnost da će doći do napadaja angine.
This magnitude of increased exposure is not expected to be clinically relevant to most patients.
Ne očekuje se da je ova razina povećanog izlaganja relevantna za većinu bolesnika.
This magnitude of reduction was observed within 4 weeks of treatment.
Ovakav opseg smanjenja opažen je unutar 4 tjedna liječenja.
This makes factor VIII less effective in controlling bleeding.
Stoga je faktor VIII manje učinkovit u kontroli krvarenja.
This makes sure that the solution flows.
Time se osigurava protok otopine.
This makes sure the insulin flows.
Tada ćete biti sigurni da inzulin protječe kroz iglu.
This makes the injection more comfortable than injecting straight from a refrigerator.
Na taj je način injiciranje puno ugodnije nego injiciranje odmah nakon vađenja iz hladnjaka.
This makes the injection more comfortable than using straight from the refrigerator.
Na taj je način injiciranje puno ugodnije nego kad se injicira odmah nakon vađenja iz hladnjaka.
This material explains the safety of the medicine, its interactions with other medicines, and includes guidance on the monitoring of liver function and management of possible symptoms of liver problems.
Taj materijal pojašnjava sigurnost lijeka, njegove interakcije s drugim lijekovima i uključuje smjernice o praćenju funkcije jetre i upravljanju simptomima bolesti jetre.
This material shall inform about the
Ovi će ih materijali informirati o:
This material will include a self-injection guide for patients, as well as an injection guide for parents or caregivers of children with the condition.
Ovaj materijal će uključiti vodič za samoubrizgavanje za bolesnike kao i vodič za injekciju za roditelje ili pružatelje skrbi djece s ovim stanjem.
This material will include information on the risk and prevention of peritonitis (inflammation of the lining of the abdomen) in patients undergoing peritoneal dialysis, arterio-venous fistula (an abnormal passageway between an artery and a vein) in patients undergoing haemodialysis, and vitamin deficiency in patients with chronic kidney disease.
Ovi će materijali uključivati informacije o riziku i prevenciji peritonitisa (upale ovojnice abdomena) u bolesnika koji se podvrgavaju peritonealnoj dijalizi, arterio-venskoj fistuli (abdominalnom prolazu između arterije i vene) u bolesnika koji se podvrgavaju hemodijalizi i deficijenciju vitamina u bolesnika sa kroničnom bolesti bubrega.
This may affect up to 1 in 100 people: irregular heartbeat
Može se javiti u do 1 na 100 osoba: nepravilni otkucaji srca
This may affect your ability to drive or operate any tools or machinery.
To može utjecati na sposobnost vožnje ili upravljanja alatima ili strojevima.
This may allow you to sleep through the effects.
Ako imate vrućicu, pijte puno vode kako biste ostali hidrirani.
This may also help to delay future worsening of your MS.
To također može pomoći u odgađanju budućeg pogoršanja Vaše MS-e.
This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition.
To se može pripisati zbrojnom učinku zbog popratnih lijekova (npr. spazmolitika) potrebnih za tu bolest.
This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition..
To bi se moglo pripisati aditivnom učinku istodobno primijenjenih lijekova potrebnih za liječenje tog stanja (npr. spazmolitika).
This may be checked by plasma assays of anti-Xa and anti-IIa activities.
Ovo se može provjeriti pretragama plazme na anti-Xa i anti-IIa aktivnost.
This may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of haemoglobin.
To se može učiniti redovitim liječničkim pregledima bolesnika, pozornim praćenjem drenaže kirurške rane te povremenim mjerenjem hemoglobina.
This may be due to a number of reasons, for example, if there is: a problem at the time your blood cells are taken for the manufacturing of Provenge.
Razlozi mogu biti svakojaki, primjerice: problem u trenutku kada su Vaše krvne stanice uzete za pripremu lijeka Provenge.
This may be due to nerve damage (called ‘peripheral neuropathy’), which is a very common side effect.
To može biti zbog oštećenja živca (nazvanog „periferna neuropatija“) što je vrlo česta nuspojava.
This may be followed by 250 mL of an acceptable acidic liquid - fruit juice (e.g., orange juice or any acidic fruit juice).
Nakon toga može se popiti 250 ml odgovarajuće kisele tekućine - voćnog soka (npr. sok od naranče ili bilo koji kiseli voćni sok).
This may be harmful for people with phenylketonuria.
Može biti štetan za osobe koje boluju od fenilketonurije.
This may be inborn, of unknown cause or due to other medicines.
ako imate povećanu sklonost krvarenju; ona može biti urođena, nepoznatog uzroka ili uzrokovana drugim lijekovima.
This may be increased by 1 mg per kg of body weight at intervals of one to two weeks.
Ta se doza može povećavati za 1 mg po kilogramu tjelesne težine u razmacima od jednog do dva tjedna.
This may be increased by up to 100 mg at intervals of one to two weeks.
Ta se doza može povećavati za do 100 mg u razmacima od jednog do dva tjedna.
This may be increased by up to 100 mg at intervals of two weeks.
Ta se doza može povećavati za do 100 mg u razmacima od dva tjedna.
This may be more likely with long-term HIV treatment, more severe damage to the immune system, overweight, or the use of alcohol or other medicines called corticosteroids.
Vjerojatnost za to mogla bi biti veća u slučaju dugotrajnog liječenja HIV-a, težih oštećenja imunološkog sustava, prekomjerne tjelesne težine, konzumacije alkohola ili primjene drugih lijekova koji se zovu kortikosteroidi.
This may be reduced to a few weeks by taking certain medicines which speed up removal of Leflunomide Winthrop from your body.
To se razdoblje može smanjiti na nekoliko tjedana ako uzimate neke lijekove koji ubrzavaju uklanjanje lijeka Leflunomide Winthrop iz tijela.
This may be used to treat fungal infections.
On se može koristiti za liječenje gljivičnih infekcija. diltiazem.
This may cause bleeding. allergic reactions
To može izazvati krvarenje. alergijske reakcije.
This may cause bleeding. if you are pregnant with more than one baby and/or are given medicines that can delay the birth of your baby, such as medicines used for high blood pressure.
To može izazvati krvarenje. ako nosite više od jednog djeteta i/ili primate lijekove koji mogu odgoditi porod, poput lijekova za visoki krvni tlak.
This may cause difficulties in breathing or swallowing
Ovo može izazvati poteškoće u disanju ili gutanju
This may cause similar side effects as seen with intraveneous and/or oral beta-blocking medicines.
Ovo može dovesti do pojave nuspojava sličnih onima zabilježenim s intravenozno (primjena u venu) i/ili oralno (primjena kroz usta) primijenjenim beta blokatorima.
This may cause similar undesirable effects as seen with systemic beta-blocking agents.
Ovo može uzrokovati slične nuspojave koje se javljaju kod primjene sustavnih beta blokatora.
This may cause weakness, being sick (vomiting), cramps, tremor and changes in heart rhythm (arrhythmias).
To može uzrokovati slabost, povraćanje, grčeve, nevoljno drhtanje i promjene u otkucajima srca (aritmije).
This may cause you symptoms such as a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Refluks se manifestira simptomimapoput boli u prsima koja se podiže do grla (žgaravica) i kiselog okusa u ustima (povrat kiseline).
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).
To može predstavljati rizik u situacijama u kojima su takve sposobnosti posebno važne (primjerice, upravljanje vozilima ili rad sa strojevima).
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machines).
To može predstavljati rizik u situacijama u kojima su takve sposobnosti posebno važne (primjerice, vožnja automobila ili rukovanje strojevima).
This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
To može predstavljati rizik u situacijama u kojima su takve sposobnosti vrlo važne (primjerice, vožnja automobila ili upravljanje strojevima).
This may happen particularly if you are a patient at risk, for example if you are elderly or if you suffer from kidney disease.
Vjerojatnost za to je povećana ako spadate u rizičnu skupinu bolesnika, primjerice ako ste stariji ili ako bolujete od bolesti bubrega.
This may happen: if you take too little Enyglid,
To se može dogoditi: ako uzmete premalo Enyglida,
This may happen: if you take too little Repaglinide Krka,
To se može dogoditi: ako uzmete premalo Repaglinida Krka,
This may happen: if you take too much Enyglid
To se može dogoditi: ako uzmete previše Enyglida
This may happen: if you take too much Repaglinide Krka
To se može dogoditi: ako uzmete previše Repaglinida Krka
This may have to be considered for patients who are on a controlled sodium diet.
O tome treba voditi računa u bolesnika na dijeti s kontroliranim (niskim) unosom natrija.
This may impair your ability to drive or operate machinery
To može umanjiti Vašu sposobnost da upravljate vozilima ili rukujete strojevima.
This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities
To može uključivati trenutnu ili nedavnu gastrointestinalnu ulceraciju, prisustvo maligne neoplazme s visokim rizikom od krvarenja, nedavna ozljeda mozga ili spinalna ozljeda, nedavni moždani, spinalni, ili oftalmološki kirurški zahvat, nedavno intrakranijalno krvarenje, poznato ili suspektno, ezofagealni varikoziteti, arteriovenske malformacije, vaskularna aneurizma, ili značajne intraspinalne ili intracerebralne vaskularne abnormalnosti
This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
To može uključivati postojeći ili nedavni gastrointestinalni ulkus, prisustnost zloćudne novotvorine s visokim rizikom od krvarenja, nedavna ozljeda mozga ili kralježnične moždine, nedavni kirurški zahvat na mozgu, kralježničnoj moždini ili oku, nedavno intrakranijalno krvarenje, potvrđeni ili sumnja na varikozitete jednjaka, arteriovenske malformacije, vaskularne aneurizme ili velike intraspinalne i intracerebralne vaskularne abnormalnosti.
This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
To može uključivati postojeći ili nedavni gastrointestinalni ulkus, prisutnost zloćudne novotvorine s visokim rizikom od krvarenja, nedavna ozljeda mozga ili kralježnične moždine, nedavni kirurški zahvat na mozgu, kralježničnoj moždini ili oku, nedavno intrakranijalno krvarenje, potvrđeni ili sumnja na varikozitete jednjaka, arteriovenske malformacije, vaskularne aneurizme ili velike intraspinalne i intracerebralne vaskularne abnormalnosti.
This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
To može uključivati postojeći ili nedavni gastrointestinalni ulkus, prisutnost zloćudne novotvorine s visokim rizikom od krvarenja, nedavna ozljeda mozga ili kralježnične moždine, nedavni kirurški zahvati na mozgu, kralježničnoj moždini ili oku, nedavno intrakranijalno krvarenje, potvrđeni ili sumnja na varikozitete jednjaka, arteriovenske malformacije, vaskularne aneurizme ili velike intraspinalne i intracerebralne vaskularne abnormalnosti.
This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
To može uključivati sadašnju ili nedavnu gastrointestinalnu ulceraciju, prisutnosti malignih novotvorina kod kojih postoji velik rizik od krvarenja, nedavne ozljede mozga ili kralježnice, nedavnog kirurškog zahvata na mozgu, kralježnici ili očima, nedavnog intrakranijalnog krvarenja, utvrđenih ili suspektnih varikoziteta jednjaka, arterijskovenskih malformacija, vaskularnih aneurizmi ili značajnih abnormalnosti intraspinalnih ili intracerebralnih krvnih žila.
This may include the provision by the MAH of stickers with invented name and batch number with each pack of the vaccine.
To može značiti da bi Nositelj odobrenja trebao nabaviti naljepnice sa zaštićenim imenom i brojem serije uz svako pakovanje cjepiva.
This may include:
, To može uključivati:
This may include:
To može uključivati:
This may increase the risk of lung oedema (accumulation of fluid in the lungs).
To može povećati rizik od plućnoga edema (nakupljanja tekućine u plućima).
This may increase your risk of serious side effects
To Vam može povećati rizik od ozbiljnih nuspojava.
This may increase your risk of side effects.
To može povećati rizik od nuspojava.
This may indicate that the ovaries over-reacted to the treatment and that large ovarian cysts developed (see also in section 2. under ‘ Ovarian Hyper-Stimulation Syndrome”).
To može značiti da su jajnici prekomjerno reagirali na liječenje te da su nastale velike ciste na jajnicima (pogledajte također u dijelu 2. pod "Sindrom hiperstimulacije jajnika (OHSS)").
This may indicate that the ovaries over-reacted to the treatment and that large ovarian cysts developed (see also in section 2. under “Ovarian Hyper- Stimulation Syndrome”).
To može značiti da su jajnici prekomjerno reagirali na liječenje te da su nastale velike ciste na jajnicima (pogledajte također u dijelu 2. pod "Sindrom hiperstimulacije jajnika (OHSS)").
This may induce metformin accumulation and may increase the risk for lactic acidosis.
To može inducirati nakupljanje metformina te povećati rizik laktacidoze.
This may involve itching, reddening of the skin or difficulty in breathing. if you are allergic to valsartan or any of the other ingredients of Dafiro this medicine (listed in section 6).
To može uključivati svrbež, crvenilo kože ili teškoće pri disanju. ako ste alergični na valsartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
This may involve itching, reddening of the skin or difficulty in breathing. if you are allergic to valsartan or any of the other ingredients of this medicine (listed in section 6).
To može uključivati svrbež, crvenilo kože ili otežano disanje. ako ste alergični na valsartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
This may involve itching, reddening of the skin or difficulty in breathing. if you are allergic to valsartan or any of the other ingredients of this medicine (listed in section 6).
To može uključivati svrbež, crvenilo kože ili teškoće pri disanju. ako ste alergični na valsartan ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).